Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 15/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | DHPS | P49366 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15940268 | 0.88 | GRM1 (0.60) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15939983 | 0.88 | GRM1 (0.60) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15940313 | 0.87 | GRM1 (0.56) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15940189 | 0.87 | GRM1 (0.56) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15940065 | 0.87 | GRM1 (0.58) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15939596 | 0.87 | GRM1 (0.58) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15940113 | 0.87 | GRM1 (0.58) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15939932 | 0.85 | GRM1 (0.56) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15939845 | 0.85 | GRM1 (0.58) | GRM1KCNH2PDE4BPDE7ADHPS | |
| SCHEMBL15940015 | 0.84 | GRM1 (0.53) | GRM1KCNH2PDE4BPDE7ADHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260448-B2 | Thienopyrimidinone derivatives as mGluR1 antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-02-16 | — | — | US | claimed |
| US-20140228565-A1 | THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-08-14 | — | — | US | claimed |
| US-9260448-B2 | Thienopyrimidinone derivatives as mGluR1 antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-02-16 | — | — | US | disclosed |
| US-20140228565-A1 | THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228565-A1 | THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS | GRM1, GRIN1, GRM2 | GRM1 1/4885KCNH2 1928/4885PDE4B 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.